Today's biologics manufacturing practices incur high costs to the drug makers, which can
contribute to high prices for patients. Timely investment in the development and …

There is a growing application of integrated and continuous bioprocessing (ICB) for
manufacturing recombinant protein therapeutics produced from mammalian cells. At first …

Continuous bioprocessing is significantly changing the biological drugs (or biologics)
manufacturing landscape by potentially improving product quality, process stability, and …

There is renewed interest in the possibility of using precipitation for initial capture of high‐
value therapeutic proteins as part of an integrated continuous downstream process …

Continuous virus inactivation (VI) has received little attention in the efforts to realize fully
continuous biomanufacturing in the future. Implementation of continuous VI must assure a …

Significant amounts of soluble product aggregates were observed during low-pH viral
inactivation (VI) scale-up for an IgG4 monoclonal antibody (mAb IgG4-N1), while small-scale …

Over the last several years, continuous manufacturing of pharmaceuticals has evolved from
bulk APIs and solid oral dosages into the more complex realm of biologics. The …

Continuous manufacturing is an indicator of a maturing industry, as can be seen by the
example of the petrochemical industry. Patent expiry promotes a price competition between …

Handling long-term dynamic variability in harvest titer is a critical challenge in continuous
downstream manufacturing. This challenge is becoming increasingly important with the …

Background Monoclonal antibodies (mAbs) currently dominate the biotherapeutic market.
This has resulted in significant efforts towards the development of a continuous integrated …